Gold Nanoparticles Crossing Blood-Brain Barrier Prevent HSV-1 Infection and Reduce Herpes Associated Amyloid-βsecretion
Infections caused by HSV-1 and their typical outbreaks invading the nervous system have been related to neurodegenerative diseases. HSV-1 infection may deregulate the balance between the amyloidogenic and non-amyloidogenic pathways, raising the accumulation of amyloid-β peptides, one of the hallmarks in the neurodegenerative diseases. An effective treatment against both, HSV-1 infections and neurodegeneration, is a major therapeutic target. Therefore, gold nanoparticles (NPAus) have been previously studied in immunotherapy, cancer and cellular disruptions with very promising results. Our study demonstrates that a new NPAus family inhibits the HSV-1 infection in a neural-derived SK-N-MC cell line model and that this new NPAus reduces the HSV-1-induced β-secretase activity, as well as amyloid-β accumulation in SK-APP-D1 modifies cell line. We demonstrated that NPAuG3-S8 crosses the blood-brain barrier (BBB) and does not generate cerebral damage to in vivo CD1 mice model. The NPAuG3-S8 could be a promising treatment against neuronal HSV-1 infections and neuronal disorders related to the Aβ peptides.
Top-30
Journals
|
1
2
|
|
|
Nanomedicine
2 publications, 7.41%
|
|
|
Molecules
2 publications, 7.41%
|
|
|
Molecular Neurobiology
2 publications, 7.41%
|
|
|
Current Pharmaceutical Design
1 publication, 3.7%
|
|
|
Polymers
1 publication, 3.7%
|
|
|
Frontiers in Bioengineering and Biotechnology
1 publication, 3.7%
|
|
|
Frontiers in Microbiology
1 publication, 3.7%
|
|
|
Microorganisms
1 publication, 3.7%
|
|
|
Vaccines
1 publication, 3.7%
|
|
|
European Physical Journal Plus
1 publication, 3.7%
|
|
|
Journal of NeuroVirology
1 publication, 3.7%
|
|
|
Global Challenges
1 publication, 3.7%
|
|
|
International Journal of Dermatology
1 publication, 3.7%
|
|
|
International Journal of Nanomedicine
1 publication, 3.7%
|
|
|
SpringerBriefs in Applied Sciences and Technology
1 publication, 3.7%
|
|
|
Contemporary Clinical Neuroscience
1 publication, 3.7%
|
|
|
Coordination Chemistry Reviews
1 publication, 3.7%
|
|
|
Journal of Drug Delivery Science and Technology
1 publication, 3.7%
|
|
|
Reviews in Medical Virology
1 publication, 3.7%
|
|
|
Toxins
1 publication, 3.7%
|
|
|
Ageing Research Reviews
1 publication, 3.7%
|
|
|
Nature Reviews Materials
1 publication, 3.7%
|
|
|
1
2
|
Publishers
|
1
2
3
4
5
6
7
|
|
|
Springer Nature
7 publications, 25.93%
|
|
|
MDPI
6 publications, 22.22%
|
|
|
Elsevier
4 publications, 14.81%
|
|
|
Taylor & Francis
3 publications, 11.11%
|
|
|
Wiley
3 publications, 11.11%
|
|
|
Frontiers Media S.A.
2 publications, 7.41%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 3.7%
|
|
|
1
2
3
4
5
6
7
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.